Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Lymphatic Vascular Structures: A New Aspect in Proliferative Diabetic Retinopathy.

Gucciardo E, Loukovaara S, Salven P, Lehti K.

Int J Mol Sci. 2018 Dec 13;19(12). pii: E4034. doi: 10.3390/ijms19124034. Review.

2.

Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing.

Garg AD, Vandenberk L, Fang S, Fasche T, Van Eygen S, Maes J, Van Woensel M, Koks C, Vanthillo N, Graf N, de Witte P, Van Gool S, Salven P, Agostinis P.

Cell Death Differ. 2017 May;24(5):832-843. doi: 10.1038/cdd.2017.15. Epub 2017 Feb 24.

3.

A Case of Abnormal Lymphatic-Like Differentiation and Endothelial Progenitor Cell Activation in Neovascularization Associated with Hemi-Retinal Vein Occlusion.

Loukovaara S, Gucciardo E, Repo P, Lohi J, Salven P, Lehti K.

Case Rep Ophthalmol. 2015 Jul 17;6(2):228-38. doi: 10.1159/000437254. eCollection 2015 May-Aug.

4.

Indications of lymphatic endothelial differentiation and endothelial progenitor cell activation in the pathology of proliferative diabetic retinopathy.

Loukovaara S, Gucciardo E, Repo P, Vihinen H, Lohi J, Jokitalo E, Salven P, Lehti K.

Acta Ophthalmol. 2015 Sep;93(6):512-23. doi: 10.1111/aos.12741. Epub 2015 Apr 21.

5.

[Stem cells in cancer].

Salvén P.

Duodecim. 2014;130(19):1983-9. Review. Finnish.

PMID:
25558619
6.

TIM-family molecules in embryonic hematopoiesis: fetal liver TIM-4(lo) cells have myeloid potential.

Syrjänen R, Petrov P, Glumoff V, Fang S, Salven P, Savolainen ER, Vainio O, Uchida T.

Exp Hematol. 2014 Mar;42(3):230-40. doi: 10.1016/j.exphem.2013.11.014. Epub 2013 Dec 4.

PMID:
24316337
7.

Concise review: endothelial stem and progenitor cells and their habitats.

Goligorsky MS, Salven P.

Stem Cells Transl Med. 2013 Jul;2(7):499-504. doi: 10.5966/sctm.2013-0005. Epub 2013 Jun 12. Review.

8.

Generation of functional blood vessels from a single c-kit+ adult vascular endothelial stem cell.

Fang S, Wei J, Pentinmikko N, Leinonen H, Salven P.

PLoS Biol. 2012;10(10):e1001407. doi: 10.1371/journal.pbio.1001407. Epub 2012 Oct 16.

9.

Dual action of TGF-β induces vascular growth in vivo through recruitment of angiogenic VEGF-producing hematopoietic effector cells.

Fang S, Pentinmikko N, Ilmonen M, Salven P.

Angiogenesis. 2012 Sep;15(3):511-9. doi: 10.1007/s10456-012-9278-9. Epub 2012 May 13.

PMID:
22581517
10.

Somatic progenitor cell vulnerability to mitochondrial DNA mutagenesis underlies progeroid phenotypes in Polg mutator mice.

Ahlqvist KJ, Hämäläinen RH, Yatsuga S, Uutela M, Terzioglu M, Götz A, Forsström S, Salven P, Angers-Loustau A, Kopra OH, Tyynismaa H, Larsson NG, Wartiovaara K, Prolla T, Trifunovic A, Suomalainen A.

Cell Metab. 2012 Jan 4;15(1):100-9. doi: 10.1016/j.cmet.2011.11.012.

11.

High serum angiogenin at diagnosis predicts for failure on long-term treatment response and for poor overall survival in non-Hodgkin lymphoma.

Fang S, Repo H, Joensuu H, Orpana A, Salven P.

Eur J Cancer. 2011 Jul;47(11):1708-16. doi: 10.1016/j.ejca.2011.02.018. Epub 2011 Mar 23.

PMID:
21439815
12.

Stem cells in tumor angiogenesis.

Fang S, Salven P.

J Mol Cell Cardiol. 2011 Feb;50(2):290-5. doi: 10.1016/j.yjmcc.2010.10.024. Epub 2010 Nov 1. Review.

PMID:
21047516
13.

The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.

Iivanainen E, Lauttia S, Zhang N, Tvorogov D, Kulmala J, Grenman R, Salven P, Elenius K.

Microvasc Res. 2009 Dec;78(3):278-85. doi: 10.1016/j.mvr.2009.06.010. Epub 2009 Jul 9.

PMID:
19596357
14.

Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth.

Purhonen S, Palm J, Rossi D, Kaskenpää N, Rajantie I, Ylä-Herttuala S, Alitalo K, Weissman IL, Salven P.

Proc Natl Acad Sci U S A. 2008 May 6;105(18):6620-5. doi: 10.1073/pnas.0710516105. Epub 2008 Apr 28.

15.

VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts.

Raisky O, Nykänen AI, Krebs R, Hollmén M, Keränen MA, Tikkanen JM, Sihvola R, Alhonen L, Salven P, Wu Y, Hicklin DJ, Alitalo K, Koskinen PK, Lemström KB.

Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):819-25. Epub 2007 Feb 8.

PMID:
17290032
16.

Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis.

He Y, Luo Y, Tang S, Rajantie I, Salven P, Heil M, Zhang R, Luo D, Li X, Chi H, Yu J, Carmeliet P, Schaper W, Sinusas AJ, Sessa WC, Alitalo K, Min W.

J Clin Invest. 2006 Sep;116(9):2344-55. Epub 2006 Aug 24.

17.

Contribution of bone marrow-derived pericyte precursor cells to corneal vasculogenesis.

Ozerdem U, Alitalo K, Salven P, Li A.

Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3502-6.

18.

[Stem cells as spare parts for humans, tomorrow's promise or nonsense].

Salvén P, Alitalo R.

Duodecim. 2004;120(17):2037-9. Finnish. No abstract available.

PMID:
15559010
19.

PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis.

Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, Lohela M, Wiig H, Salven P, Pajusola K, Eriksson U, Alitalo K.

Blood. 2004 Nov 15;104(10):3198-204. Epub 2004 Jul 22.

PMID:
15271796
20.

Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells.

Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P.

Blood. 2004 Oct 1;104(7):2084-6. Epub 2004 Jun 10.

21.

Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis.

He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K.

Cancer Res. 2004 Jun 1;64(11):3737-40.

22.

CD14 and TNfa promoter polymorphisms in patients with acute arthritis. Special reference to development of chronic spondyloarthropathy.

Repo H, Anttonen K, Kilpinen SK, Palotie A, Salven P, Orpana A, Leirisalo-Repo M.

Scand J Rheumatol. 2002;31(6):355-61.

PMID:
12492251
23.

High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.

Ruotsalainen T, Joensuu H, Mattson K, Salven P.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1492-5.

24.

VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells.

Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S.

Blood. 2003 Jan 1;101(1):168-72. Epub 2002 Aug 15.

PMID:
12393704
25.

Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion.

Salven P, Hattori K, Heissig B, Rafii S.

FASEB J. 2002 Sep;16(11):1471-3. Epub 2002 Jul 18.

PMID:
12205052
26.

Angiogenic and lymphangiogenic molecules in hematological malignancies.

Orpana A, Salven P.

Leuk Lymphoma. 2002 Feb;43(2):219-24. Review.

PMID:
11999550
27.

Angiogenesis in lymphoproliferative disorders.

Salven P.

Acta Haematol. 2001;106(4):184-9. Review.

PMID:
11815716
28.

Endotoxins induce and interferon alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells.

Salven P, Anttonen K, Repo H, Joensuu H, Orpana A.

FASEB J. 2001 May;15(7):1318-20. No abstract available.

PMID:
11344126
29.

Interferon alpha-2a therapy in 18 hemangioblastomas.

Niemelä M, Mäenpää H, Salven P, Summanen P, Poussa K, Laatikainen L, Jääskeläinen J, Joensuu H.

Clin Cancer Res. 2001 Mar;7(3):510-6.

31.

Vascular permeability factor/vascular endothelial growth factor in nasal polyps.

Vento SI, Wolff CH, Salven PJ, Hytönen ML, Ertama LO, Malmberg CH.

Acta Otolaryngol Suppl. 2000;543:170-4.

PMID:
10909012
32.

Major surgery increases serum levels of vascular endothelial growth factor only temporarily.

Bondestam J, Salven P, Jääskela-Saari H, Ikonen T, Lepäntalo M, Mattila S, Joensuu H.

Am J Surg. 2000 Jan;179(1):57-9.

PMID:
10737580
33.
34.

Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6.

Ojala PM, Tiainen M, Salven P, Veikkola T, Castaños-Vélez E, Sarid R, Biberfeld P, Mäkelä TP.

Cancer Res. 1999 Oct 1;59(19):4984-9.

35.

VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.

Valtola R, Salven P, Heikkilä P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K.

Am J Pathol. 1999 May;154(5):1381-90.

36.

Serum VEGF levels in women with a benign breast tumor or breast cancer.

Salven P, Perhoniemi V, Tykkä H, Mäenpää H, Joensuu H.

Breast Cancer Res Treat. 1999 Jan;53(2):161-6.

PMID:
10326793
37.
38.

Blood platelets and serum VEGF in cancer patients.

Vermeulen PB, Salven P, Benoy I, Gasparini G, Dirix LY.

Br J Cancer. 1999 Jan;79(2):370-3. No abstract available.

39.

Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.

Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimäki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A.

Thromb Haemost. 1998 Jul;80(1):171-5.

PMID:
9684805
40.

Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.

Salven P, Lymboussaki A, Heikkilä P, Jääskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H.

Am J Pathol. 1998 Jul;153(1):103-8.

41.
42.

Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3.

Jussila L, Valtola R, Partanen TA, Salven P, Heikkilä P, Matikainen MT, Renkonen R, Kaipainen A, Detmar M, Tschachler E, Alitalo R, Alitalo K.

Cancer Res. 1998 Apr 15;58(8):1599-604.

43.

Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance.

Salven P, Heikkilä P, Anttonen A, Kajanti M, Joensuu H.

Mod Pathol. 1997 Nov;10(11):1128-33.

PMID:
9388064
44.
45.

Serum vascular endothelial growth factor is often elevated in disseminated cancer.

Salven P, Mänpää H, Orpana A, Alitalo K, Joensuu H.

Clin Cancer Res. 1997 May;3(5):647-51.

46.

Enhanced expression of vascular endothelial growth factor in metastatic melanoma.

Salven P, Heikkilä P, Joensuu H.

Br J Cancer. 1997;76(7):930-4.

47.

Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis.

Salvén P, Joensuu H, Heikkilä P, Matikainen MT, Wasenius VM, Alanko A, Alitalo K.

Br J Cancer. 1996 Jul;74(1):69-72.

48.

Genes protecting from cancer.

Salvén P, Alitalo K.

Ann Med. 1990 Jun;22(3):143-4. No abstract available.

PMID:
2393548
49.

Primary structure of the brain alpha-spectrin.

Wasenius VM, Saraste M, Salvén P, Erämaa M, Holm L, Lehto VP.

J Cell Biol. 1989 Jan;108(1):79-93. Erratum in: J Cell Biol 1989 Mar;108(3):following 1175.

50.

Transforming and membrane proteins.

Lehto VP, Wasenius VM, Salvén P, Saraste M.

Nature. 1988 Aug 4;334(6181):388. No abstract available.

PMID:
3405286

Supplemental Content

Loading ...
Support Center